Fig 1.

Scheme of the procedure applied for mutation analysis of lavage samples from patients with malignant diseases. When a mutation was detected in the lavage specimen by next-generation sequencing (NGS), it was confirmed by safe sequencing system (SafeSeqS) and analysis of the corresponding tumor tissue. If no mutation was detected by NGS, singleplex methods (SafeSeqS for all 12 patients and digital droplet polymerase chain reaction for six patients) were used to detect a specific mutation previously determined in tumor tissue of 12 patients. (*) Excluded because of previous tubal ligation, germline mutation, or two or more malignant tumors present. MUT, mutation.